138 related articles for article (PubMed ID: 18946956)
41. RETIRED: Mid-trimester amniocentesis fetal loss rate.
Wilson RD; Langlois S; Johnson JA; ;
J Obstet Gynaecol Can; 2007 Jul; 29(7):586-590. PubMed ID: 17623573
[TBL] [Abstract][Full Text] [Related]
42. [Amniotic fluid analysis in the 2d pregnancy trimester].
Treffers PE; Leschot NJ; Verjaal M
Ned Tijdschr Geneeskd; 1981 Mar; 125(13):489-93. PubMed ID: 7231574
[No Abstract] [Full Text] [Related]
43. [Fetomaternal transfusions in early pregnancy].
du Bois A; Rasenack R; Siebers JW; Geyer H; Quaas L
Z Geburtshilfe Perinatol; 1991; 195(2):71-5. PubMed ID: 1716034
[TBL] [Abstract][Full Text] [Related]
44. Mid-pregnancy amniocentesis.
Ju KS; Lee SK; Kim SB; Lee JH
Asia Oceania J Obstet Gynaecol; 1985 Mar; 11(1):55-63. PubMed ID: 3893404
[No Abstract] [Full Text] [Related]
45. Pregnancy loss rates after midtrimester amniocentesis.
Wapner RJ; Evans MI; Platt LD
Obstet Gynecol; 2007 Mar; 109(3):780; author reply 780-1. PubMed ID: 17329536
[No Abstract] [Full Text] [Related]
46. Pregnancy loss rates after midtrimester amniocentesis.
Wilson RD
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):451-2; author reply 452-3. PubMed ID: 17267851
[No Abstract] [Full Text] [Related]
47. Pregnancy loss rates after midtrimester amniocentesis.
Smith L
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):452; author reply 452-3. PubMed ID: 17267853
[No Abstract] [Full Text] [Related]
48. Pregnancy loss rates after midtrimester amniocentesis.
Nadel A
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):451; author reply 452-3. PubMed ID: 17267852
[No Abstract] [Full Text] [Related]
49. Consensus Conference on Anti-D Prophylaxis. Edinburgh, United Kingdom, 8-9 April 1997. Papers and abstracts.
Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():iv, 1-44. PubMed ID: 10328662
[No Abstract] [Full Text] [Related]
50. [Is it advisable to produce anti-Rh0(D) immunoglobulin for the prevention of hemolytic disease of the newborn? (apropos the article by A. A. Mikhaĭlova and N. Ia. Klimova)].
Olovnikova NI; Chertkov IL
Gematol Transfuziol; 1993 Mar; 38(3):38-40. PubMed ID: 8020736
[No Abstract] [Full Text] [Related]
51. [Rhesus immunoprevention by means of immunoglobulin anti-D].
Maas DH; Schneider
Med Monatsschr; 1975 Aug; 29(8):340-7. PubMed ID: 813106
[No Abstract] [Full Text] [Related]
52. Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.
Wu Y; Wu Y; Yang Y; Chen B; Li J; Guo G; Xiong F
Front Immunol; 2021; 12():698541. PubMed ID: 35003054
[TBL] [Abstract][Full Text] [Related]
53. Constriction of the umbilical cord as a cause of fetal demise following midtrimester amniocentesis.
Robertson RD; Rubinstein LM; Wolfson WL; Lebherz TB; Blanchard JB; Crandall BF
J Reprod Med; 1981 Jun; 26(6):325-7. PubMed ID: 7252953
[TBL] [Abstract][Full Text] [Related]
54. Pregnancy loss rates after midtrimester amniocentesis.
Nicolaides K
Obstet Gynecol; 2007 Mar; 109(3):780; author reply 780-1. PubMed ID: 17329535
[No Abstract] [Full Text] [Related]
55. Consequences for fetus and neonate of maternal red cell allo-immunisation.
Howard H; Martlew V; McFadyen I; Clarke C; Duguid J; Bromilow I; Eggington J
Arch Dis Child Fetal Neonatal Ed; 1998 Jan; 78(1):F62-6. PubMed ID: 9536844
[TBL] [Abstract][Full Text] [Related]
56. Reproductive outcome following amniocentesis for genetic indications.
Porreco RP; Young PE; Resnik R; Cousins L; Jones OW; Richards T; Kernahan C; Matson M
Am J Obstet Gynecol; 1982 Jul; 143(6):653-60. PubMed ID: 7091237
[No Abstract] [Full Text] [Related]
57. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
[TBL] [Abstract][Full Text] [Related]
58. The physician as a risk factor in midtrimester amniocentesis.
Hecht F
N Engl J Med; 1982 Jun; 306(25):1553. PubMed ID: 7078619
[No Abstract] [Full Text] [Related]
59. Unexpected suppression of anti-Fya and prevention of hemolytic disease of the fetus and newborn after administration of Rh immune globulin.
Branch DR; Scofield TL; Moulds JJ; Swanson JL
Transfusion; 2011 Apr; 51(4):816-9. PubMed ID: 20946183
[TBL] [Abstract][Full Text] [Related]
60. Haemolytic disease of the newborn.
Whitfield CR; Lee D
BMJ; 1990 Mar; 300(6727):814. PubMed ID: 2157515
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
